Social Ties, Stigma and Clinic Rules Steer Opioid Treatment Choices After Prison

For people leaving jail or prison with opioid use disorder, the first months of freedom are among the most dangerous of their lives. Medications for opioid use disorder, or MOUD, such as methadone and buprenorphine, dramatically improve outcomes during this window, bridging patients from carceral treatment into community care and protecting against fatal overdose and return to incarceration. Yet a new qualitative study published in SSM – Mental Health reveals that whether people actually stay on these lifesaving medications depends on far more than clinical effectiveness. Drawing on in-depth interviews with 28 adults released from a statewide Northeastern US carceral system, researchers led by Amelia Bailey of Brown University mapped how factors at every level of the social-ecological model — individual, interpersonal, community and structural — converge to shape which medication people prefer, whether they can access it, and whether they intend to keep taking it at all.

The social-ecological framework, first articulated by developmental psychologist Urie Bronfenbrenner, holds that health decisions are never made in a vacuum. Instead, they emerge from interacting layers of influence: personal beliefs and motivations at the core, surrounded by family and peer networks, then the clinics and neighborhoods where people live, and finally the policies, laws and dominant social attitudes that govern treatment itself. The research team applied a modified version of this model to understand how recently incarcerated patients navigate a treatment landscape that has shifted dramatically in the past five years. Federal regulators have expanded take-home methadone doses, reducing the number of days patients must appear in person at an opioid treatment program, and removed the cap on how many patients a provider may prescribe buprenorphine to. Long-acting injectable buprenorphine has also entered the market, bringing its own barriers of cost and limited clinic availability.

Between March and August 2025, the team conducted semi-structured interviews averaging 50 minutes with adults who had received methadone or buprenorphine during an incarceration in the past year. Participants were recruited through opioid treatment programs, office-based providers and recovery centers across the state, with purposive efforts to balance representation by medication type. The sample, on average, had been released just over five months before the interview, was 37.6 years old on average, and included 16 men and 12 women. Most participants were White and non-Latino. At the time of interview, 25 of the 28 participants were receiving methadone and only three were on buprenorphine, even though most had received methadone during incarceration as well. Interviews were transcribed, coded using template-style thematic analysis with both deductive and inductive codes, and analyzed in NVivo until thematic saturation was achieved.

The first and most personal theme concerned perceived benefits. Participants continued MOUD when they felt it clearly worked — helping them avoid withdrawal, illicit opioid use and reincarceration, three outcomes that participants described as deeply intertwined. Many reported that methadone curbed their cravings more effectively than buprenorphine, a difference that proved decisive. One participant who could not reach a methadone clinic after release discontinued treatment entirely because buprenorphine, though easier to obtain with only monthly provider visits, did not adequately suppress his cravings; he resumed methadone only after moving closer to a clinic. This finding underscores a technical point with major clinical implications: patient preference is not merely about convenience but about pharmacological fit, and when the medication that works best is inaccessible, some patients opt for no medication at all.

Paradoxically, nearly all participants — even those who credited MOUD with stabilizing their recovery — expressed an intention to taper off within the next couple of years. Many described methadone or buprenorphine as a band-aid, a short-term tool rather than a chronic therapy, reflecting what the authors identify as an internalized abstinence narrative. This belief had concrete consequences for treatment selection: some participants rejected long-acting injectable buprenorphine precisely because its monthly dosing removed the daily control that would let them stop when they chose. The researchers argue that distinguishing between patients whose desire to discontinue is clinically congruent and those whose desire is driven by stigma or structural barriers is essential for designing interventions that improve retention during the highest-risk period.

At the interpersonal level, the study found that supportive family involvement was invaluable but rare. A few participants relied on relatives for transportation to daily methadone dosing, a logistical lifeline that made treatment feasible. Far more common was stigma within families, where methadone was perceived as simply swapping one drug for another. Several participants concealed their treatment from loved ones, describing it as embarrassing, and this concealment bred isolation. In one striking account, a participant who had been stable after a previous release — employed, housed, engaged in methadone treatment — stopped the medication because of his mother’s disapproval, relapsed into illicit opioid use, and experienced worsening mental health. Others deliberately shrank their social circles to avoid substance use triggers or exposure. Against this backdrop, many participants emphasized self-reliance, framing their recovery as something they had to accomplish alone, and some even preferred buprenorphine’s relative lack of wraparound services because it demanded less dependence on institutions.

Community and organizational factors proved to be powerful levers of access. Housing proximity to an opioid treatment program, access to a working vehicle, and reliable bus routes determined whether daily methadone dosing was realistic. Free transportation services funded through public insurance helped some participants, but others were unaware of these programs, lost passes, or found multi-bus commutes prohibitive. One woman who had to make lengthy near-daily trips by bus concluded that methadone simply did not work for someone without a car and expressed regret over starting it during incarceration, saying she would prefer a monthly injectable so she would not have to worry about dosing every day. The physical environment around clinics also mattered: visible drug activity near treatment sites triggered discomfort and cravings for some patients, deterring them from clinics even when those clinics were close to home.

Clinic practices themselves shaped treatment trajectories. Participants described anxiety over whether they could receive same-day dosing at community intake, hearsay about waitlists, unclear urine drug screening policies, and fear of missing doses when entering residential programs. Although no participant experienced significant gaps in care after reaching a clinic, the psychological cost of fearing withdrawal was real, and for some it motivated a desire to taper off entirely. One participant, facing a warned urine drug screen from his buprenorphine prescriber shortly after release, chose to stop treatment and continue using before later switching to methadone. These accounts illustrate how restrictive or opaque clinic rules can convert a treatable condition into a cycle of disengagement, use and re-engagement.

At the structural level, the fentanyl-dominant drug supply emerged as a decisive force. Participants who were still using opioids feared precipitated withdrawal if they initiated buprenorphine with fentanyl in their system, rendering buprenorphine and its injectable formulation non-viable options in their eyes. Methadone, by contrast, was seen as robust in the fentanyl era, though a few participants described developing a double habit — concurrent methadone and illicit fentanyl use that pushed their methadone doses upward and left them uncomfortable if either substance was unavailable. Methadone also carried a unique legal advantage: its mandatory counseling satisfied probation requirements for some participants, helping them avoid re-arrest, a benefit no buprenorphine recipient reported. Meanwhile, expanded take-home methadone policies motivated engagement for some, but patients with instability indicators often could not accrue take-homes quickly enough, and the threat of losing privileges after hospitalization or reincarceration discouraged others. Systemic stigma in employment and housing further eroded commitment, with participants questioning whether they could be hired as nurses or in other careers while on methadone.

The authors conclude that MOUD preferences and intentions after incarceration are entangled with multilevel barriers, and that improving retention will require interventions at every layer: pre-release education to counter misinformation and stigma, stronger linkage to MOUD-affirming recovery communities and peer support specialists, transportation solutions, and lower-barrier delivery models including community-based post-release dosing. Peer support specialists were described as helpful by the few participants who encountered them, but their scarcity reflects the slow integration of these roles into treatment systems. Given that discontinuing MOUD sharply elevates overdose risk, particularly when cessation occurs early, the stakes of preference-congruent care could not be higher. This study offers a detailed, patient-centered map of why people leaving incarceration choose, keep or abandon their medications — knowledge the authors say is essential for building treatment systems that keep people alive through the perilous transition home.

Subject of Research: Social-ecological determinants of medication preferences and receipt for opioid use disorder after incarceration

Article Title: Social-ecological factors shape preferences for and receipt of medications to treat opioid use disorder in the post-incarceration period

Article References: Bailey, A., Hughto, J. M., Kelly, P. J., Dunsiger, S. I., & Martin, R. A. (2026). Social-ecological factors shape preferences for and receipt of medications to treat opioid use disorder in the post-incarceration period. SSM – Mental Health, 10, Article 100705. https://doi.org/10.1016/j.ssmmh.2026.100705

Image Credits: AI Generated

DOI: 10.1016/j.ssmmh.2026.100705

Keywords: opioid use disorder, methadone, buprenorphine, post-incarceration, social-ecological model, stigma, overdose risk, fentanyl, opioid treatment programs, peer support, reentry, qualitative research